Overview
- Third-quarter revenue rose to about €1.51–€1.52 billion, with a narrowed net loss of €28.7 million and a nine-month loss of €831.1 million.
- Full-year revenue guidance increased to €2.6–€2.8 billion, yet the company still anticipates a net loss due to heavy development spending.
- R&D guidance was trimmed to €2.0–€2.2 billion as investment concentrates on late-stage oncology programs, including ADCs and the bispecific candidate Pumitamig.
- BioNTech received a $1.5 billion upfront from Bristol Myers Squibb for the Pumitamig collaboration, recognized about $700 million of related revenue in Q3, and cites potential additional payments of up to $2 billion through 2028.
- Liquid funds stood at €16.7 billion, and the CureVac takeover process is progressing after antitrust clearance with an exchange offer open until December 3, alongside $370 million settlement payments each to CureVac and GSK.